Short-term paroxetine treatment does not alter the motor response to levodopa in PD

Neurology. 2005 May 24;64(10):1797-8. doi: 10.1212/01.WNL.0000161841.41885.80.

Abstract

The authors examined the motor effects of 2 weeks of paroxetine, a serotonin reuptake inhibitor (SSRI), and placebo on responses to 2-hour levodopa infusions in 14 subjects with Parkinson disease. Paroxetine did not affect tapping scores or dyskinesia. Baseline walking speed (preinfusion) increased on paroxetine, often associated with an increased subjective perception of worsened balance.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Accidental Falls / prevention & control
  • Aged
  • Brain / drug effects
  • Brain / metabolism
  • Brain / physiopathology
  • Cross-Over Studies
  • Dizziness / chemically induced
  • Dizziness / metabolism
  • Dizziness / physiopathology
  • Dopamine / metabolism
  • Dopamine Agents / pharmacology
  • Double-Blind Method
  • Drug Interactions / physiology
  • Female
  • Gait Disorders, Neurologic / drug therapy
  • Gait Disorders, Neurologic / etiology
  • Gait Disorders, Neurologic / physiopathology
  • Humans
  • Levodopa / pharmacology*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Parkinson Disease / psychology
  • Paroxetine / adverse effects
  • Paroxetine / pharmacology*
  • Presynaptic Terminals / drug effects
  • Presynaptic Terminals / metabolism
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Serotonin / metabolism
  • Treatment Failure
  • Vestibular Diseases / chemically induced
  • Vestibular Diseases / metabolism
  • Vestibular Diseases / physiopathology

Substances

  • Dopamine Agents
  • Serotonin Uptake Inhibitors
  • Serotonin
  • Paroxetine
  • Levodopa
  • Dopamine